Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2022

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2022-12-30: Form 6-K; Period of report 2022-12-30; Description DIRECTOR/PDMR SHAREHOLDING; Document a2529l.htm.
  • 2022-12-28: Form 6-K; Period of report 2022-12-28; Description CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL; Document a9768k.htm.
  • 2022-12-28: Form 6-K; Period of report 2022-12-28; Description IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS; Document a9766k.htm.
  • 2022-12-21: Form 6-K; Period of report 2022-12-21; Description IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER; Document a3935k.htm.
FiledFormPeriod of reportDescriptionDocument
2022-12-306-K2022-12-30DIRECTOR/PDMR SHAREHOLDINGa2529l.htm
2022-12-286-K2022-12-28CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLLa9768k.htm
2022-12-286-K2022-12-28IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERSa9766k.htm
2022-12-216-K2022-12-21IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCERa3935k.htm
2022-12-216-K2022-12-21LYNPARZA APPROVED IN EU FOR PROSTATE CANCERa3945k.htm
2022-12-196-K2022-12-19ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW MEa0818k.htm
2022-12-196-K2022-12-19ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE ADa0816k.htm
2022-12-196-K2022-12-19IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENTa0814k.htm
2022-12-196-K2022-12-19UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CELa0812k.htm
2022-12-196-K2022-12-19FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HFa0810k.htm
2022-12-156-K2022-12-15UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDAa7757j.htm
2022-12-086-K2022-12-08CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCERa0640j.htm
2022-12-016-K2022-12-01TOTAL VOTING RIGHTSa3063i.htm
2022-12-016-K2022-12-01BLOCK LISTING INTERIM REVIEWa3027i.htm
2022-11-306-K2022-11-30ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITEa9784h.htm
2022-11-296-K2022-11-29ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICSa9015h.htm
2022-11-236-K2022-11-23DIRECTOR/PDMR SHAREHOLDINGa3966h.htm
2022-11-146-K2022-11-14ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRICa2284g.htm
2022-11-146-K2022-11-14IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTCa2282g.htm
2022-11-146-K2022-11-14LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPCa2279g.htm
2022-11-146-K2022-11-11IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCERa0678g.htm
2022-11-106-K2022-11-10YTD AND Q3 2022 RESULTSa9087f.htm
2022-11-096-K2022-11-09FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMAa8048f.htm
2022-11-046-K2022-11-04BEYFORTUS (NIRSEVIMAB) APPROVED IN EUa2959f.htm
2022-11-016-K2022-11-01TOTAL VOTING RIGHTSa9080e.htm
2022-10-266-K2022-10-26CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTSa1534e.htm
2022-10-256-K2022-10-25UPDATE ON MESSINA PHASE III TRIALa9518d.htm
2022-10-246-K2022-10-24IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCERa8410d.htm
2022-10-036-K2022-10-03TOTAL VOTING RIGHTSa5767b.htm
2022-09-306-K2022-09-30BOARD COMMITTEE CHANGESa2623b.htm
2022-09-276-K2022-09-27KOSELUGO APPROVED IN JAPAN FOR NF1a8021a.htm
2022-09-276-K2022-09-27TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMAa6982a.htm
2022-09-236-K2022-09-23ULTOMIRIS APPROVED IN EU FOR GMGa4296a.htm
2022-09-226-K2022-09-22LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCERa2781a.htm
2022-09-216-K2022-09-21TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMAa0640a.htm
2022-09-206-K2022-09-20EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENTa9503z.htm
2022-09-166-K2022-09-16DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINTa7317z.htm
2022-09-166-K2022-09-16NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMPa7324z.htm
2022-09-166-K2022-09-16EVUSHELD POSITIVE CHMP OPINION IN EUa6834z.htm
2022-09-066-K2022-09-06FORXIGA APPROVED IN CHINA FOR CKDa1936y.htm
2022-09-066-K2022-09-06IMFINZI APPROVED IN US FOR BILIARY TRACT CANCERa1934y.htm
2022-09-016-K2022-09-01TOTAL VOTING RIGHTSa9870x.htm
2022-08-306-K2022-08-30EVUSHELD APPROVED FOR COVID-19 IN JAPANa6168x.htm
2022-08-306-K2022-08-30FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HFa4731x.htm
2022-08-306-K2022-08-30FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGEa4733x.htm
2022-08-256-K2022-08-25ULTOMIRIS APPROVED IN JAPAN FOR GMGa1489x.htm
2022-08-256-K2022-08-25TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCERa1498x.htm
2022-08-256-K2022-08-25LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCERa1546x.htm
2022-08-166-K2022-08-16LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPELa1478w.htm
2022-08-156-K2022-08-15ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02a9414v.htm
2022-08-126-K2022-08-12ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLCa8365v.htm
2022-08-116-K2022-08-11ACQUISITION OF TENEOTWO COMPLETEDa6385v.htm
2022-08-086-K2022-08-08ENHERTU APPROVED IN THE US FOR HER2-LOW MBCa2207v.htm
2022-08-046-K2022-08-04LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCERa9051u.htm
2022-08-016-K2022-08-01DIRECTOR/PDMR SHAREHOLDINGa5152u.htm
2022-08-016-K2022-08-01TOTAL VOTING RIGHTSa4618u.htm
2022-08-016-K2022-08-01DIRECTOR/PDMR SHAREHOLDINGa4409u.htm
2022-07-296-K2022-07-29CHAIR SUCCESSIONa1651u.htm
2022-07-296-K2022-06-30FORM 6-Kazn-20220331x6k.htm
2022-07-256-K2022-07-25TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMAa5305t.htm
2022-07-256-K2022-07-25ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMGa5302t.htm
2022-07-256-K2022-07-25ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBCa5300t.htm
2022-07-196-K2022-07-19ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBCa9430s.htm
2022-07-056-K2022-07-05ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGERa2649r.htm
2022-07-016-K2022-07-01TOTAL VOTING RIGHTSa0240r.htm
2022-06-306-K2022-06-30IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCERa7302q.htm
2022-06-276-K2022-06-27ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVALa2121q.htm
2022-06-276-K2022-06-27LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCERa2118q.htm
2022-06-216-K2022-06-21EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTSa6051p.htm
2022-06-066-K2022-06-06ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCERa7067n.htm
2022-06-016-K2022-06-01BLOCK LISTING INTERIM REVIEWa6142n.htm
2022-06-016-K2022-06-01TOTAL VOTING RIGHTSa6003n.htm
2022-05-206-K2022-05-20DIRECTOR/PDMR SHAREHOLDINGa3066m.htm
2022-05-096-K2022-05-09APPOINTMENT OF JOINT CORPORATE BROKERSa7750k.htm
2022-05-066-K2022-05-06DIRECTOR/PDMR SHAREHOLDINGa6380k.htm
2022-05-056-K2022-05-05ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCERa4273k.htm
2022-05-056-K2022-05-05FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINTa4269k.htm
2022-05-056-K2022-05-05ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINTa3797k.htm
2022-05-046-K2022-05-04IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTCa1996k.htm
2022-05-036-K2022-05-03TOTAL VOTING RIGHTSa1280k.htm
2022-04-296-K2022-04-29RESULT OF AGMa9458j.htm
2022-04-296-K2022-04-29ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTSa7934j.htm
2022-04-296-K2022-04-29FIRST QUARTER 2022 RESULTSa7847j.htm
2022-04-286-K2022-04-28ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMGa6681j.htm
2022-04-276-K2022-04-27ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCERa4543j.htm
2022-04-256-K2022-04-25TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBOa1691j.htm
2022-04-196-K2022-04-19ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLCa5058i.htm
2022-04-016-K2022-04-01TOTAL VOTING RIGHTSa9835g.htm
2022-03-296-K2022-03-29ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSALa3157g.htm
2022-03-286-K2022-03-28EVUSHELD APPROVED IN THE EU FOR COVID-19a1576g.htm
2022-03-256-K2022-03-25DIRECTOR/PDMR SHAREHOLDINGa0893g.htm
2022-03-246-K2022-03-24EVUSHELD POSITIVE EU CHMP OPINIONa9765f.htm
2022-03-246-K2022-03-24UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERAa8862f.htm
2022-03-236-K2022-03-23NOTICE OF AGMa6601f.htm
2022-03-236-K2022-03-23FORM 6-Ktm229472d1_6k.htm
2022-03-176-K2022-03-17SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRISa1097f.htm
2022-03-146-K2022-03-14LYNPARZA APPROVED IN US FOR EARLY BREAST CANCERa5904e.htm
2022-03-146-K2022-03-14UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPSa5906e.htm
2022-03-096-K2022-03-09DIRECTOR/PDMR SHAREHOLDINGa2114e.htm
2022-03-076-K2022-03-07DIRECTOR/PDMR SHAREHOLDINGa8835d.htm
Advertisement